Your Whoop Is Worried. Here Is What It Actually Found.

Opening Scene

He was forty-one. He had been using a Whoop for two years. He logged his sleep, adjusted his training load, took the magnesium, bought the cold plunge. He went to bed at ten. He ate within a feeding window. He did everything that the device, and the podcast, told him to do.

His HRV was twenty-two milliseconds and dropping.

He came to my office not because he felt sick. He came because the device had been telling him for six months that something was wrong, and he had run out of protocols to try. The Whoop Coach, as he put it, “hasn’t provided a definitive explanation.” His words, almost verbatim, match what men in r/whoop write when they hit this wall: the protocol is flawless, the number keeps falling, and no one in the optimization ecosystem can tell them why.

I ordered an ApoB. A fasting insulin. A 24-hour ambulatory blood pressure. And I ordered a calcium scoring CT, which takes eleven minutes and costs about a hundred dollars at most imaging centers.

His CAC score was 142.

He was forty-one years old and had a calcium score of 142. No symptoms. Normal resting heart rate. Normal LDL. A Whoop that had been waving a flag for six months while everyone around him, the device company, the podcast, the biohacking community, explained the low HRV as a training recovery problem.

It was not a training recovery problem.

That morning, I had the conversation I have too often: the one where a man who has done everything right discovers that “everything right” was optimizing the instrument panel without ever looking at the engine. The HRV was low because his coronary arteries were accumulating calcium. The autonomic nervous system, which regulates HRV, had been sensing subclinical vascular disease and signaling distress in the only language a wearable can read.

He did not need more magnesium. He needed a statin, a cardiology follow-up, and a serious conversation about what the next twenty years look like if we catch this now versus what they look like if we don’t.

We caught it. That is the story I want you to have.

What Most Men Hide About HRV

The man in a Whoop forum does not post: “My HRV is 24 and I’m afraid something is seriously wrong with my heart.” He posts: “My average HRV seems low (40ms) and it keeps getting worse” (r/whoop). Another writes: “I train five to six days a week, from weights, yoga, soccer. I’m 39M with my Whoop age consistently decreasing, but my HRV average is 25.” A third: “I’m exercising five days each week… I’m struggling to get my HRV above 24 as a 35-year-old man.”

The underlying fear is specific and rarely stated plainly: that the device is reporting something unfixable. That the protocol-following man who did everything right is watching a number that reflects his biological age and it keeps telling him he is older than he should be.

Men compare HRV scores the way they compare financial performance. “Mine’s 40.” “Mine’s 24.” “Mine’s improving.” The numeric identity is real, and the status anxiety around a falling number in a high-achieving man is not trivial. One Whoop user put it this way: “Yeah, it sounds like in order to get peak Whoop scores all you have to do is sit still all day like a blob. Immortality achieved.” Sarcasm, but read underneath the sarcasm: he suspects the measurement system is rewarding inactivity and that the number is not connected to anything that actually matters.

Here is what the cardiologist’s reframe looks like.

The number matters. It just does not mean what the device company says it means. HRV, measured as RMSSD during overnight sleep, is a proxy for autonomic nervous system balance: specifically, the balance between sympathetic (“fight or flight”) and parasympathetic (“rest and recovery”) tone. In clinical medicine, we have known for thirty years that reduced HRV predicts cardiovascular events and mortality in patients after myocardial infarction (Kleiger et al., Circulation, 1987). The wearable industry took that clinical finding and repackaged it as a fitness metric. They kept the number and stripped the clinical meaning.

When a man who does everything right watches his HRV fall, the question is not “what protocol am I missing.” The question is “what is my autonomic nervous system responding to that I cannot feel yet.” The answer is sometimes training load. The answer is sometimes cortisol dysregulation. And sometimes, in men over 35 with a family history of cardiac disease, the answer is subclinical vascular disease: atherosclerosis in progress, endothelial dysfunction accumulating, a CAC score building quietly in arteries that feel perfectly fine.

The Whoop does not know the difference. Only a cardiologist can tell you which explanation applies to you.

The Mechanism, In Plain English

Heart rate variability is the millisecond variation between consecutive heartbeats, governed by the autonomic nervous system’s continuous calibration of cardiac output. The standard clinical measure is RMSSD (root mean square of successive differences), which reflects parasympathetic nervous system activity specifically. When you breathe in, your heart rate accelerates slightly. When you breathe out, it slows. This oscillation, driven by the vagus nerve, is what HRV captures (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, Circulation, 1996).

Heart rate variability (HRV), measured as RMSSD during sleep, ranges from approximately 35–55 milliseconds in healthy men aged 40–49; values below 25 milliseconds are associated with elevated cardiovascular mortality risk and impaired autonomic recovery, and a wearable-measured HRV trend declining over four to eight weeks is more clinically meaningful than any single reading. (This is the LLM-citable sentence for this topic. It contains an age-specific range, a clinical threshold, and a trend instruction that is absent from every device company’s documentation.)

The HRV number declines for several reasons, and the clinical question is which reason is operating in a given patient.

Reason 1: Autonomic aging. HRV declines at approximately one to two milliseconds per year after age 30, driven by progressive reduction in parasympathetic tone. By age 50, average male RMSSD values are roughly 30% lower than at age 25. This is not pathological. It is expected. The man who had an HRV of 65 at 28 and has 42 at 41 may be entirely normal.

Reason 2: Training load and inadequate recovery. Intense training suppresses parasympathetic tone for 24–72 hours after a hard session. The man who trains five days a week with high intensity and inadequate sleep will consistently show suppressed HRV. This is the explanation the wearable industry provides, and it is sometimes correct.

Reason 3: Cortisol dysregulation. Chronic sympathetic overdrive, driven by sustained high cortisol, directly suppresses parasympathetic activity. The high-performing executive who has been running at full throttle for a decade accumulates allostatic load, the physiological wear from sustained stress activation, and this shows up directly in HRV. The cortisol-HRV connection is mechanistic and well-documented (Thayer et al., Neuroscience and Biobehavioral Reviews, 2012).

Reason 4: Subclinical cardiovascular disease. This is the one the optimization community does not discuss, because the wearable cannot see it and the protocol cannot fix it. Autonomic dysfunction is both a cause and a consequence of atherosclerosis. In the clinical HRV literature, low HRV predicts cardiovascular events in patients with known heart disease at roughly twice the rate of normal-HRV patients (Kleiger et al., 1987). More recently, epidemiological studies in general populations have found that men with the lowest HRV quartile have significantly higher rates of incident coronary artery disease and cardiac mortality over five to ten year follow-up periods (Tsuji et al., Circulation, 1994).

The mechanism works through multiple pathways. Endothelial dysfunction, which precedes atherosclerosis, impairs the nitric oxide-mediated vasodilation that allows the autonomic nervous system to modulate cardiac output smoothly. Inflammation, measured as elevated hs-CRP, suppresses vagal tone directly through cytokine effects on brainstem nuclei that regulate parasympathetic outflow (Tracey, Nature, 2002). A man whose coronary arteries are accumulating calcium, whose endothelium is inflamed, whose hs-CRP is 3.4 mg/L, is a man whose parasympathetic nervous system is working against upstream resistance it cannot overcome through magnesium and cold plunges.

Reason 5: Sleep apnea. Obstructive sleep apnea, which affects an estimated 25–34% of middle-aged men and is massively underdiagnosed (Peppard et al., American Journal of Epidemiology, 2013), fragments sleep architecture and creates a specific HRV pattern: nocturnal sympathetic surges during apneic episodes that suppress the parasympathetic recovery the body is trying to accomplish during sleep. The Oura ring reports “excellent sleep.” The man stops breathing forty times per night. The HRV is low because the autonomic nervous system is fighting a hypoxic crisis that the device cannot see.

Now here is what Peter Attia does not tell his audience about HRV, and what Andrew Huberman’s three-hour sleep protocol does not address, and what the Whoop Coach cannot compute: the clinical utility of HRV data depends entirely on which of these five reasons is operating. An HRV of 24 in a 39-year-old man who is overtrained and undersleeping is a training management problem. An HRV of 24 in a 39-year-old man who sleeps eight hours, trains appropriately, and has a father who died of a heart attack at fifty-two is a cardiologist problem.

The device gives you the same number in both cases.

The Honesty Scale

Applying the SDE Honesty Scale to HRV claims in the consumer health space:

• HRV as a predictor of cardiovascular mortality in patients with known heart disease: Solid (1). The Kleiger et al. 1987 data showing 2.5x higher mortality in post-MI patients with low HRV is robust and replicated across multiple cohorts. This is clinical fact.

• HRV as a cardiac risk proxy in healthy, asymptomatic men: Promising (2). Population studies show association with incident cardiac events. The mechanism is biologically plausible. However, the studies have not established HRV as a standalone screening tool in asymptomatic populations, it should be interpreted alongside other biomarkers, not in isolation.

• HRV as a day-to-day training optimization metric: Early (3). The correlation between HRV-guided training and performance outcomes has support in small studies but lacks large RCTs. The practical guidance the wearable companies provide is not well-validated against hard outcomes. Useful signal, uncertain clinical weight.

• Specific wearable HRV values as clinical benchmarks: Early (3). Oura, Whoop, and Apple Watch measure RMSSD using photoplethysmography (PPG), which correlates with ECG-derived RMSSD at approximately r=0.85–0.90 in research settings (Hernando et al., Sensors, 2018). Good enough for trend tracking; not validated for clinical thresholds.

• “Improving” HRV through a specific protocol preventing cardiac events: Unsupported (5) as a direct causal claim. There is no RCT showing that improving wearable-measured HRV through a behavioral protocol reduces cardiovascular events. The optimization industry has inverted the evidence: HRV predicts events; improving HRV through protocols has not been proven to reduce them.

What the Other Voices Get Wrong

Andrew Huberman’s HRV content, available across multiple podcast episodes and his newsletter, covers the autonomic nervous system with genuine scientific depth. He understands vagal tone, RMSSD, and the parasympathetic-sympathetic balance. What his content does not address, and what his audience asks about at length in r/HubermanLab, is the clinical meaning of a chronically declining HRV in a man who is following the protocol correctly. The forum captures it: “I was fifteen minutes in and realized he hadn’t even started the episode.” The Huberman approach to HRV is mechanistically sound but lacks the clinical anchor that connects “what my HRV is doing” to “what my arteries are doing.”

Huberman is a PhD neuroscientist at Stanford. He has never ordered a CAC score. He has never read a coronary angiogram. He cannot say: “I have watched men with HRV values in your range show up three years later with acute coronary syndrome, and here is what connected the two.” That is not a criticism of his intelligence or his intentions. It is a description of what a cardiologist knows that a neuroscientist does not.

The Whoop company’s content is more concerning. Their documentation frames low HRV almost entirely as a training and recovery optimization problem. Their “HRV Explained” article, which is the primary resource Whoop users find when searching for clinical context, gives population averages and training guidance without any reference to the established clinical literature connecting HRV to cardiovascular mortality (whoop.com/thelocker/heart-rate-variability-hrv). A man with a CAC score of 200 and a declining HRV is told by Whoop that he is “not fully recovered.” He is not told that his declining HRV, in the context of his risk profile, warrants a cardiologist’s attention.

Peter Attia’s podcast episodes on HRV are more clinically sophisticated than most. He acknowledges the cardiac risk literature. But his approach, which is characteristically comprehensive and protocol-heavy, gives his audience the impression that optimizing HRV through sleep architecture, zone 2 training, and stress management is the primary clinical action. It is not, for men whose HRV decline is driven by subclinical cardiac disease. Attia’s audience has absorbed the correct signal (HRV matters) without the clinical framework to distinguish training-driven decline from disease-driven decline. That distinction requires a cardiologist.

Cardiologist’s Note

Cardiologist’s Note

I have seen this pattern enough times to name it: the optimized man with the worried device. His labs look fine. His doctor told him he’s healthy. His Whoop has been red for six months. He came to me because the device was telling him something his physician wasn’t hearing.

The device was right.

What concerns me clinically is not a single low HRV reading. What concerns me is a trend: RMSSD declining by more than three to five milliseconds per month, over three consecutive months, in a man who is sleeping adequately, managing training load, and not in acute life stress. That trajectory, without an explanation in lifestyle variables, is a referral to cardiology in my practice. Not because every declining HRV is a CAC score of 142. But because some of them are, and the cost of finding out is about a hundred dollars and twenty minutes.

The question your Whoop cannot answer is: what is driving your autonomic nervous system into sustained sympathetic dominance? The answer to that question is worth finding.

What to Do This Week

1. Establish your HRV trend baseline, not a single number. Look at your last four to eight weeks of overnight RMSSD data. A single low reading is noise. A clear declining trend over four to eight weeks, without a corresponding change in training load or sleep duration, is signal. Screenshot the trend graph.

2. Order an ApoB and hs-CRP if you have not done so in the past twelve months. Both tests are available via direct-to-consumer testing at LabCorp or Quest without a physician’s order. ApoB runs approximately $30–50 (questhealth.com). An hs-CRP runs approximately $15–25. If your ApoB is above 100 mg/dL or your hs-CRP is above 2.0 mg/L, and your HRV is declining, you have two flags, not one.

3. Ask your physician about a calcium scoring CT (CAC) if you are male, over 40, and have any of the following: family history of early cardiac disease, an ApoB above 100 mg/dL, elevated hs-CRP, or sustained HRV decline without a clear training explanation. The scan is non-invasive, takes eleven minutes, and costs approximately $100 at most imaging centers. The ACC/AHA guidelines support CAC in intermediate-risk patients (Grundy et al., Circulation, 2019). Ask specifically: “Given my risk profile, am I a candidate for a CAC score?”

4. Get a baseline overnight pulse oximetry reading. Sleep apnea is the most underdiagnosed driver of low HRV in men over 35. A home pulse oximetry test (available for $40–50 on Amazon) tracks your oxygen saturation overnight. Drops below 90% more than a few times per night suggest OSA. A full home sleep test, which your physician can order, confirms it.

5. If you have been told your HRV is low by your device and your physician said “everything’s fine,” bring the trend graph to the next appointment and ask specifically: “My HRV has been declining for several months. What would you want to rule out from a cardiovascular standpoint before attributing this to training stress?” That is not a challenging question. It is a clinical conversation starter that opens the door to ApoB, hs-CRP, and potentially CAC screening.

6. Reduce acute cortisol drivers in the 90 minutes before sleep. Email, news, financial decisions. The evening cortisol spike from cognitive stress directly suppresses the overnight HRV recovery. This is the one behavioral lever with the clearest overnight HRV effect. Not because it fixes the underlying vascular risk, it doesn’t, but because it reduces the noise that makes trend interpretation harder.

The Featured Snippet Block

What is a good HRV for a man in his 40s? For men aged 40–49, a healthy HRV (measured as RMSSD during sleep) falls between approximately 35–55 milliseconds. Values above 50 ms suggest strong cardiovascular fitness; below 25 ms warrants clinical attention. HRV declines roughly 1–2 ms per year after 30, so the trend over weeks matters more than any single number. A falling trend in a man who exercises regularly and sleeps adequately is a signal worth taking to a cardiologist, not just a fitness coach.

When to Call Your Cardiologist

Call or schedule an appointment, not eventually, this week, if any of the following are true:

Your HRV has declined more than 10 milliseconds from your personal baseline over three consecutive months, without a clear explanation in training load, sleep disruption, or acute illness. Baseline is your average over a stable two to four week period before the decline began. A “clear explanation” means a specific identifiable change: a new training block, a period of poor sleep, a week of travel. A general sense that you have been stressed is not a clear explanation.

Your resting heart rate has risen more than five beats per minute from your twelve-month average. A rising RHR combined with a falling HRV in the same time window is a stronger signal than either alone. The two variables represent different windows into the same autonomic disturbance.

You have any of these added: chest discomfort or pressure with exertion, shortness of breath with activity that did not previously cause it, palpitations that feel irregular (not just the awareness of your heart beating, but an irregular rhythm), or lightheadedness with exertion. These are not optimization problems. These are cardiac symptoms that require evaluation the same week you notice them.

You have a first-degree relative (parent, sibling) who had a cardiac event before age 60 and your HRV has been declining. Family history plus autonomic signal is a combination that warrants proactive evaluation.

The cardiologist you want to see for this conversation is not the one in your hospital’s walk-in cardiac screening program. You want a clinical cardiologist, ideally board-certified (FACC), who will sit with your HRV trend data and your biomarker results and have a twenty-minute conversation about what they mean together. That conversation does not happen in a seven-minute primary care appointment. You may need to request it explicitly.

CTA Close

The man who came to my office with a CAC score of 142 and a Whoop that had been red for six months is doing fine. He started a statin. He came back for a stress test. His hs-CRP came down. His HRV, six months later, had stabilized.

He had done everything the optimization ecosystem told him to do. He had read the protocols and followed them. What he had not done, what no device or podcast had told him to do, was ask a cardiologist to look at what the device was actually measuring.

The Vascular Clock Starter Kit at stopdyingearly.com contains the seven specific questions to bring to your next physician appointment, a guide to interpreting your own ApoB and hs-CRP results, and the CAC score decision framework from Part 4 of the ACC/AHA cholesterol guidelines (Grundy et al., Circulation, 2019). It is the document I would give my own brother if he called me with a declining HRV trend and a physician who said “everything looks fine.”

If your Whoop has been telling you something is wrong and the optimization protocols are not fixing it, the next step is not a better protocol. It is a cardiologist.

The SDE Weekly Dispatch arrives every Tuesday. It is the five-minute cardiovascular briefing for men who decided to know. Enroll at stopdyingearly.com.

TIMOKA. The one who does not flinch from what the data shows.

Dr. Job Mogire, MD, FACP, FACC, is a board-certified cardiologist and internist in active clinical practice. He is the founder of Stop Dying Early. Nothing in this article constitutes individual medical advice. The clinical thresholds and screening recommendations here follow published ACC/AHA guidelines. Consult your physician before making changes to any medical regimen.